A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.
Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup's medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).
Six months after Esai Alzheimer’s disease drug Leqembi received accelerated FDA approval, the agency has awarded the drug full approval. While the agency’s regulatory decision sets precedent for other Alzheimer’s drugs, it also flags serious safety risks.
A Health Affairs study discovered that nearly two-thirds of Medicare Advantage psychiatrist networks, or 64.6%, were narrow in 2019. Comparatively, about 43.1% of Medicaid managed care networks were narrow and 39.5% of ACA Marketplaces were narrow.
Two VCs from Merck Global Health Innovation Fund recently offered fundraising advice for digital health companies. They told these firms to expect slower funding timelines, urged them not to be afraid of down or flat rounds, and advised them to spend time nailing down the specifics of their growth narrative.